吉西他滨联合奥沙利铂治疗晚期铂类耐药卵巢癌效果观察

Clinical efficacy of gemcitabine combined with oxaliplatin on advanced platinum resistant ovarian cancer

目的探讨吉西他滨联合奥沙利铂治疗晚期铂类耐药卵巢癌患者的临床疗效。方法选择确诊为晚期复发上皮性卵巢癌患者45例，采用奥沙利铂100mg／m2，第1天，静脉滴注3h；吉西他滨850mg／m2，第1、8天，静脉滴注30min；3周为1个周期，完成2～4个周期，按照实体瘤评价标准和WHO抗癌药物不良反应进行疗效评价和不良反应评估。结果45例患者中完全缓解（CR）3例，部分缓解（PR）13例，疾病稳定（SD）20例，疾病进展（PD）9例，有效率为35．6％，疾病控制率为80．0％；主要不良反应为贫血、血小板减少、胃肠道反应，大多数为轻、中度。结论吉西他滨联合奥沙利铂治疗晚期复发上皮性卵巢癌临床疗效确切，不良反应可耐受。

Objective To investigate the clinical efficacy of gemcitabine combined with oxaliplatin （GEMOX） on platinum resistant epithelial ovarian cancer. Methods A total of 45 recurrent epithelial ovarian cancer patients were selected. All the patients were treated with gemeitabine （850 mg/m2 ） on the first and eight day, and oxaliplatin （100 mg/m2） on the first day, three weeks as a therapeutic cyclic ,2 -4 therapeutic cycles were performed. The clinical efficacy and adverse reactions were recorded. Results Among the 45 cases, 3 cases of complete remission, 13 cases of partial remission, 20 cases of stable disease, 9 cases of progression of disease. The objective response rate was 35.6% , and the disease control rate was 80.0%. The dose-limiting toxicities were anemia, thrombocytopenia, nausea/nomiting, which were moderate and manageable. Conclusions Gemcitabine combined with oxaliplatin showes obvious clinical efficacy in the treatment of advanced recurrent epithelial ovarian cancer with toler- able adveres effects.